

20 June 2018

ANANDA DEVELOPMENTS PLC
(“Ananda” or the “Company”)

**Completion of Placing to raise GBP 930,000
and
Application for Admission to trading on the NEX Exchange Growth Market**

Ananda Developments plc (TIDM: ANA) is pleased to announce that it has applied for the 329,166,666 ordinary shares of 0.2 pence each in the Company (“Ordinary Shares”) to be admitted to trading on the NEX Exchange Growth Market (“Admission”). It is expected that Admission will become effective and that dealings in the Ordinary Shares will commence at 8.00am, on 4 July 2018.

Company Information

The Company has been established to invest in the developing market for medicinal or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the USA, as well as other countries around the world, changing their laws to allow for products containing constituents of Medicinal Cannabis to be developed, approved and sold.

Ananda’s investment strategy is to invest in companies, projects or products that are either progressing medicinal or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products. Ananda will look to invest in companies or projects in Israel, Canada and the Netherlands.

In conjunction with Admission, Peterhouse Capital Limited has completed a placing to raise GBP930,000 (before expenses), on behalf of the Company, through the issue of 206,666,666 Ordinary Shares at a price of 0.45p per Ordinary Share.

Directors

Brief biographical details of the Directors are set out below:

Melissa Josephine Sturgess, Executive Director (aged 51)

Melissa Sturgess holds a BSc and an MBA and has many years of experience as a director of AIM and ASX quoted companies, mainly involved in the acquisition, structuring and financing of natural resources deals across Africa. She was most recently a key driver in the successful recapitalisation of Messaging International plc during 2016 which subsequently changed its name to SigmaRoc Plc, acquired a building materials business via a reverse takeover and raised £50 million from a range of investors in the Channel Islands and the UK.

Charles Waite Morgan, Executive Director (aged 58)

Charles Morgan is a resources and technology venture capitalist who has identified emerging sectors and acquired early stage and strategic positions in a wide range of ventures around the globe. He has a proven track record in identifying early stage commercial opportunities and acting as a corporate catalyst, acquiring strategic assets and positions, partnering with regional and technology experts, securing teams of appropriate executives and funds to build and develop projects and companies.

Mr Morgan started his career in futures broking in London with M.L. Doxford & Co and left to join merchant bank Morgan Grenfell Limited in Sydney, Australia before moving to broking with ANZ

McCaughan Dyson Limited in Melbourne and London. He then joined BZW Securities Limited in London before going back to Australia to form Morgan McFarlane a licensed securities dealer which raised equity funds for (mainly) Perth based mining and oil exploration companies.

Mr Morgan is involved in investing in various businesses and start-ups in the UK and San Francisco including Neuro-Bio Ltd (discoverer of cause and potential drug for Alzheimer's, Parkinson's and Motor Neurone Disease), TGMatrix (shipper and transport matching engine), Brytlyt (GPU based data base analytics), PensionBee (gathering people's various pensions into one), Teamable (social media based employment), Headnote (de-chequing legal firms in the US).

He is currently Chair of both Grand Gulf Energy Limited and Whitebark Energy Ltd.

John Michael Treacy, Non-executive Director (aged 36)

Mr Treacy is a London-based experienced small cap financier who specialises in working with growing companies. He qualified as a solicitor in the London office of a major international law firm where he specialised in Capital Markets and Mergers & Acquisitions. From there he moved to practice corporate finance in the advisory teams of several prominent UK brokerages where he acted as an adviser to a number of AIM companies and advised on numerous IPOs, acquisitions, debt restructurings and placings.

Dr. Inbar Maymon Pomeranchik, PhD, Non-executive Director (aged 40)

Dr. Pomeranchik holds a PhD in plant sciences molecular biology from the Hebrew University of Jerusalem and a multi-disciplinary post-doctorate from Weizmann Institute, combining drug biochemistry with plant science. After 15 years of molecular & genetic research and development Inbar has a hands-on experience in all aspects of the Biotech industry: from academic research to commercial project lead, from small startups to large corporations.

More recently, Dr Pomeranchik founded Biodiligence Limited, a private company, which provides consultancy services in the field of biotechnology, agricultural technology within the Medicinal Cannabis space for venture capitalists, private equity investors and family offices.

Senior Investment Adviser

On Admission, the Company's Senior Investment Adviser will be Dr. Eli David Schmill, PhD.

Dr. Schmill holds a BSc in Mathematics and Physics from the City University of New York; a PhD in Cellular and Molecular Biology from the Johns Hopkins University School of Medicine. He was a Senior Staff Fellow at the National Institute of Child Health at the National Institute of Health and post-doctoral fellowship at the John Hopkins University.

Dr. Schmill has over thirty years of direct, global and senior management experience in all aspects of the BioPharma/Biotechnology industry. His career has included academic, government, private industry, advisory board and consulting activities. He has directed programs in research and development, technology transfer, pilot processes and facilities, good manufacturing practice, quality assurance, quality control, regulatory affairs as well as manufacturing and operations. He has successfully led programs to develop and register several Biotechnology products in the world-wide market including the United States and the EU. In recent years, he has been active in the emerging Medical Cannabis industry, where his background in BioPharma drug development and registration is directly applicable.

Directors' Interests

On Admission the interests of the Directors and their immediate families and, so far as they are aware having made due and careful enquiries, of persons connected with them (all of which are beneficial, unless otherwise stated) (so far as is known to the Directors, or could with reasonable diligence be ascertained by them) (within the meaning of sections 252 to 254 of the UK Companies Act 2006) in the Issued Share Capital are and will be as follows:

<i>Director</i>	<i>Number of Ordinary Shares on Admission</i>	<i>% of Ordinary Shares in issue on Admission</i>
Melissa Josephine Sturgess*	47,222,222	14.35
Charles Waite Morgan	22,500,000	6.84
John Michael Treacy	nil	nil
Inbar Maymon Pomeranchik	nil	nil

*including Ordinary Shares held by members of her family and in the name of Palace Trading Investments Limited, a company which is beneficially owned by Melissa Sturgess

Significant Shareholders

In addition to the Directors' interests, the Board are aware of the following persons who will, directly or indirectly, jointly or severally, be interested in 3 per cent. or more of the issued Ordinary Shares at Admission:

<i>Name</i>	<i>Number of Ordinary Shares on Admission</i>	<i>% of Ordinary Shares in issue on Admission</i>
Jarvis Nominees Limited	48,888,889	14.85%
Lynchwood Nominees Limited	35,000,000	10.63%
Mr Edward Nealon	22,222,222	6.75%
Trium Capital Limited	16,666,667	5.06%
Redmayne Bentley	15,000,000	4.56%
Nomura International Limited	11,111,111	3.38%
Pershing Nominees Limited	11,111,111	3.38%

Approximately 56.37 per cent of the Company's issued share capital will be in public hands at Admission.

Sector classification:

Financial Services

Company registered office:

Ananda Developments PLC
6th Floor
60 Gracechurch Street
London
EC3V 0HR
United Kingdom

Company telephone number:

+44 (0)739 269 6517

A copy of the Company's Admission Document will be available at www.anadadevelopments.com and at www.nexexchange.com.

The Directors of the Company accept responsibility for the contents of this announcement.

ENDS

For further information, please contact:

Ananda Developments plc
Melissa Sturgess
Jeremy Sturgess-Smith

+44 (0)739 269 6517